Sanofi Shares Emerge as Europe's Most Compelling Pharma Value Play

Analysts name Sanofi Europe's best-valued large-cap healthcare stock ahead of Q1 results, forecasting beats on revenue and EPS. Key price target is 100 euros.

As the April earnings season approaches, market analysts are sharpening their focus on the French pharmaceutical giant Sanofi. The firm's stock is currently highlighted by research firm Jefferies as the most attractively valued large-cap healthcare name across European markets. This assessment is grounded in expectations for robust operational performance in the near term.

The confidence is reflected in reiterated bullish stances from major institutions. Both Jefferies and Deutsche Bank have reaffirmed their "buy" ratings, each setting a unified price target of 100 euros. With the stock closing at 79.05 euros in the previous session, this target implies significant potential upside. Analyst optimism is primarily fueled by forecasts for the first quarter. Market observers anticipate that Sanofi will surpass consensus revenue estimates by approximately 3%, with adjusted earnings per share expected to beat expectations by an even wider margin of 5%. Key growth drivers continue to be the established therapies Dupixent and Lantus.

Strategic Pipeline and Long-Term Outlook

Beyond near-term quarterly figures, the company's long-term strategic direction is drawing increased investor scrutiny. There is a growing demand for clarity regarding the lifecycle management of the blockbuster drug Dupixent. Central concerns include the period following the loss of market exclusivity between 2031 and 2032, as well as the future trajectory of Sanofi's existing alliance with Regeneron.

Concurrently, the clinical development pipeline is gaining prominence. The progress of the asthma treatment Lunsekimig is under particular watch. Advances in this program are viewed as a critical component for securing the company's market position beyond its current portfolio of products.

Following a share price decline of roughly 18% over the past year, analysts view the current valuation level as an attractive entry point. The official release of first-quarter results, scheduled for late April, is expected to provide the next fundamental catalyst for the company's valuation.